Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Editas Medicine Inc (NASDAQ: EDIT) closed the day trading at $3.89 up 9.58% from the previous closing price of $3.55. In other words, the price has increased by $9.58 from its previous closing price. On the day, 5.01 million shares were traded. EDIT stock price reached its highest trading level at $3.92 during the session, while it also had its lowest trading level at $3.56.
Ratios:
For a better understanding of EDIT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 4.05 whereas as Long-Term Debt/Eq ratio is at 3.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 03 ’25 when Burkly Linda sold 710 shares for $2.60 per share. The transaction valued at 1,843 led to the insider holds 69,490 shares of the business.
Parison Amy sold 458 shares of EDIT for $1,189 on Sep 03 ’25. The SVP, Chief Financial Officer now owns 16,369 shares after completing the transaction at $2.60 per share. On Sep 03 ’25, another insider, O’Neill Gilmore Neil, who serves as the CEO of the company, sold 5,592 shares for $2.60 each. As a result, the insider received 14,517 and left with 274,690 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 349789440 and an Enterprise Value of 192423440. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.99 while its Price-to-Book (P/B) ratio in mrq is 17.72. Its current Enterprise Value per Revenue stands at 4.946 whereas that against EBITDA is -1.249.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.24, which has changed by 0.15088761 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $3.80, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 38.56%, while the 200-Day Moving Average is calculated to be 98.69%.
Shares Statistics:
Over the past 3-months, EDIT traded about 2.39M shares per day on average, while over the past 10 days, EDIT traded about 3583180 shares per day. A total of 89.92M shares are outstanding, with a floating share count of 89.11M. Insiders hold about 0.90% of the company’s shares, while institutions hold 47.44% stake in the company. Shares short for EDIT as of 1757894400 were 7561998 with a Short Ratio of 3.17, compared to 1755216000 on 8202599. Therefore, it implies a Short% of Shares Outstanding of 7561998 and a Short% of Float of 8.430000399999999.
Earnings Estimates
Editas Medicine Inc (EDIT) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.26, with high estimates of $0.11 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.68 and -$2.22 for the fiscal current year, implying an average EPS of -$2.0. EPS for the following year is -$0.93, with 7.0 analysts recommending between -$0.63 and -$1.18.
Revenue Estimates
12 analysts predict $4.94M in revenue for. The current quarter. It ranges from a high estimate of $25M to a low estimate of $500k. As of. The current estimate, Editas Medicine Inc’s year-ago sales were $61k
A total of 12 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $55.74M, while the lowest revenue estimate was $9.2M, resulting in an average revenue estimate of $20.57M. In the same quarter a year ago, actual revenue was $32.31M
